bt 474  (CLS Cell Lines Service GmbH)


Bioz Verified Symbol CLS Cell Lines Service GmbH is a verified supplier
Bioz Manufacturer Symbol CLS Cell Lines Service GmbH manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    CLS Cell Lines Service GmbH bt 474
    Apoptotic effect determined via ( a ) caspase 3/7 cleavage activity (without magnetic treatment) and ( b ) intracellular Ca 2+ concentration of free siRNA, siRNA/Fe x O y /NIO, free siRNA with anti-tumor agent, siRNA/Fe x O y /NIO with anti-tumor agent and free anti-tumor agent with (M+) and without (M-) magnetic treatment (* = the values of the samples containing siRNA/Fe x O y /NIO + anti-tumor agent and the value of the respective anti-tumor agent were analyzed using a t -test, with all data showing p < 0.05 considered significant); ( c ) representative fluorescent images (using the Calbryte-520 Assay Kit) showing occurring apoptosis (light green) of <t>BT-474</t> cells after administration of ( 1 ) siRNA/Fe x O y /NIO with erlotinib, ( 2 ) free siRNA with erlotinib, ( 3 ) erlotinib and ( 4 ) control cells and a subsequent magnetic treatment.
    Bt 474, supplied by CLS Cell Lines Service GmbH, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bt 474/product/CLS Cell Lines Service GmbH
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    bt 474 - by Bioz Stars, 2023-11
    86/100 stars

    Images

    1) Product Images from "In-Vitro Application of Magnetic Hybrid Niosomes: Targeted siRNA-Delivery for Enhanced Breast Cancer Therapy"

    Article Title: In-Vitro Application of Magnetic Hybrid Niosomes: Targeted siRNA-Delivery for Enhanced Breast Cancer Therapy

    Journal: Pharmaceutics

    doi: 10.3390/pharmaceutics13030394

    Apoptotic effect determined via ( a ) caspase 3/7 cleavage activity (without magnetic treatment) and ( b ) intracellular Ca 2+ concentration of free siRNA, siRNA/Fe x O y /NIO, free siRNA with anti-tumor agent, siRNA/Fe x O y /NIO with anti-tumor agent and free anti-tumor agent with (M+) and without (M-) magnetic treatment (* = the values of the samples containing siRNA/Fe x O y /NIO + anti-tumor agent and the value of the respective anti-tumor agent were analyzed using a t -test, with all data showing p < 0.05 considered significant); ( c ) representative fluorescent images (using the Calbryte-520 Assay Kit) showing occurring apoptosis (light green) of BT-474 cells after administration of ( 1 ) siRNA/Fe x O y /NIO with erlotinib, ( 2 ) free siRNA with erlotinib, ( 3 ) erlotinib and ( 4 ) control cells and a subsequent magnetic treatment.
    Figure Legend Snippet: Apoptotic effect determined via ( a ) caspase 3/7 cleavage activity (without magnetic treatment) and ( b ) intracellular Ca 2+ concentration of free siRNA, siRNA/Fe x O y /NIO, free siRNA with anti-tumor agent, siRNA/Fe x O y /NIO with anti-tumor agent and free anti-tumor agent with (M+) and without (M-) magnetic treatment (* = the values of the samples containing siRNA/Fe x O y /NIO + anti-tumor agent and the value of the respective anti-tumor agent were analyzed using a t -test, with all data showing p < 0.05 considered significant); ( c ) representative fluorescent images (using the Calbryte-520 Assay Kit) showing occurring apoptosis (light green) of BT-474 cells after administration of ( 1 ) siRNA/Fe x O y /NIO with erlotinib, ( 2 ) free siRNA with erlotinib, ( 3 ) erlotinib and ( 4 ) control cells and a subsequent magnetic treatment.

    Techniques Used: Activity Assay, Concentration Assay